News Conference News ESC 2024 Stop-or-Not: It’s OK to Tailor RAS Inhibitor Use Around Noncardiac Surgery Todd Neale August 30, 2024
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Opinion Editor's Corner ESC 2022 What’s Going to Be Hot at ESC 2022? Shelley Wood August 22, 2022
News Conference News ESC 2021 New ESC Prevention Guidelines Focus on Tailored, Escalating Therapy Michael O'Riordan September 03, 2021
News Conference News ESC 2021 Finerenone Reduces CV Outcomes in Patients With Early CKD, Diabetes: FIGARO-DKD Michael O'Riordan August 28, 2021
News Conference News ESC 2020 In Long-term, Real-world Data, CABG Bests PCI for Diabetic Patients With MVD Yael L. Maxwell September 01, 2020
News Conference News ESC 2019 New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises Michael O'Riordan September 04, 2019
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019
News Conference News ESC 2018 Sobering News From Europe: CVD Risk Factors Are on the Rise or Holding Firm Todd Neale August 27, 2018
News Conference News ESC 2018 ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients Todd Neale August 26, 2018
News Conference News ESC 2017 CABG Appears Superior to PCI for Patients With Type 1 Diabetes, Multivessel Disease Todd Neale August 26, 2017
News Conference News ESC 2015 ESC Congress 2015: Presentations Sift Clinical Wheat From Chaff September 09, 2015
News Conference News ESC 2015 Ezetimibe Benefits Diabetics, and Does Not Increase Risk of New-Onset Diabetes Yael L. Maxwell September 01, 2015
News Conference News ESC 2015 TECOS: No Differences in Heart Failure Outcomes When Sitagliptin Added to Usual Care in Diabetics Yael L. Maxwell August 31, 2015
News Conference News RESET: Largest Study to Date of Xience, Cypher Shows Noninferiority August 31, 2011